BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Almac Group's Strengthened Facilities Accommodates Demand of Late Stage API Manufacture


10/24/2013 6:29:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

24 October 2013 -- Almac is pleased to report that the expansion of its API manufacturing facilities has allowed significant growth in its late stage manufacturing service.

The facility upgrade included installation of two 1,000L reactors and state-of-the-art pressure filter dryer, which now allows production of highly potent API manufacture up to 500kg with a dedicated nitrogen jet mill for micronisation.

Denis Geffroy, VP Business Development, commented: “Over the past few years, Almac’s API business has continued to grow at a double digit pace. The facility expansion was much needed and the results are already striking with several Phase III and Commercial projects awarded.”

Almac’s clients also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. This year Almac has completed its first joint commercial API and Drug Product manufacture which demonstrated the advantages of integrated operations.

“Today, our API business is made of 30% late phase and commercial projects, compared to just 5% 3 years ago, which gives a clear indication that our strategy to invest through expansion was the right one.” added Denis.

Almac will be exhibiting at CPhI Europe – Hall 4.2, Stand L08.

About Almac

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,300 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with US operations based in Pennsylvania, North Carolina and California.

To learn more about Almac please visit www.almacgroup.com, e-mail info@almacgroup.com or follow us on Twitter at https://twitter.com/AlmacGroup.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES